Editorial review · United States
Insulin
Source review:
Approval and product status
Several FDA-approved insulin products exist, including highly similar versions called biosimilars
The name insulin covers many FDA-approved products. They can differ in the amount of medicine, how long they work, how they enter the body, and what their labels allow.
This is the status described in the dated review. It is not a live FDA database check.
What was measured in people?
- Health outcomes · Strong
- Long-term studies that assigned people to groups by chance support closely monitored insulin treatment for specific groups with diabetes.
- Body effects · Strong
- Studies describe when each product starts working, reaches its strongest effect, and wears off.
A change in a hormone or body signal does not by itself prove a health benefit.
Limits that matter
Not independently medically reviewed. This tool does not recommend treatment.
Hypoglycemia means dangerously low blood sugar. It can be severe and life-threatening. Product mix-ups and changes without medical guidance can cause serious harm. This guide does not give dose calculations, correction factors, injection steps, or advice for changing an insulin plan.
Still unknown: One insulin plan is not right for everyone. Products, schedules, targets, and treatment levels vary by person and product. Evidence for one product, group, or plan does not support switching products on your own. It also does not show that every product can be exchanged freely or used for non-medical reasons.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Exact product records in this review
These are selected records, not every product or form. A route means how a product enters the body.
Humalog
- Form
- Several strengths and delivery forms listed in the label
- Route
- Injection under the skin. Humalog U-100 can also be used in some insulin pumps. Its label allows medical staff to give the U-100 form through a vein after dilution and with close monitoring. The U-200 form must not be used through a vein.
- Use and limits
- Diabetes treatment for the people and uses listed in the current Humalog label. This example does not describe every insulin product.
Published label: May 2025
Read the published Humalog FDA label (PDF)What the research shows
The Diabetes Control and Complications Trial (DCCT) put 1,441 people with type 1 diabetes into groups by chance. It compared an intensive insulin plan with a less intensive plan. It followed them for about 6.5 years. The intensive plan lowered the risk of new or worsening eye, kidney, and nerve problems. It also led to two to three times as many severe low-blood-sugar events. Insulin is essential for type 1 diabetes. Insulin treats other forms of diabetes too.
Read all Insulin claims and their limitsSources used in the full review
A source is not support for every claim. Use the claim links above or the full review to check what each source supports.
- Insulin: patient and product overview
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- HUMALOG (insulin lispro) label, updated June 2026
DailyMed · National Library of Medicine · Drug label · 2026
Source accessed
- HUMALOG (insulin lispro) FDA prescribing information, revised 05/2025
U.S. Food and Drug Administration · Drug label · 2025
Source accessed
- The effect of intensive treatment of diabetes on long-term complications in insulin-dependent diabetes mellitus
PubMed · New England Journal of Medicine · Randomized trial · 1993
Source accessed
- Hypoglycemia in the Diabetes Control and Complications Trial
PubMed · Diabetes · Randomized trial · 1997
Source accessed
- FDA approves the first rapid-acting insulin biosimilar product for diabetes
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- Biosimilars basics for patients
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- 2026 WADA Prohibited List
World Anti-Doping Agency · Anti-doping · 2026
Source accessed